Parkinson's disease therapy : Tailoring choices for early and late disease, young and old patients
Identifieur interne : 001A01 ( Main/Merge ); précédent : 001A00; suivant : 001A02Parkinson's disease therapy : Tailoring choices for early and late disease, young and old patients
Auteurs : Joseph Jankovic [États-Unis]Source :
- Clinical neuropharmacology [ 0362-5664 ] ; 2000.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
Advances in the understanding of basal ganglia circuitry and its altered function in disease states such as Parkinson's disease (PD), coupled with new insights into the mechanisms of cell death and new findings from therapeutic clinical trials, are being translated into clinical practice. Although levodopa (L-Dopa) remains the most effective drug in the symptomatic treatment of PD, the emergence of side effects, particularly motor fluctuations and dyskinesias, limits its usefulness. Therefore, many parkinsonologists now advocate therapeutic strategies designed to delay the onset of L-Dopa therapy to delay the onset of L-Dopa-related motor complications. The therapeutic approach to PD, however, must be individualized and based on factors such as age of the patient, stage of the disease, and degree of interference of the symptoms with social and occupational functioning, associated symptoms such as cognitive impairment, and response to treatment. This review summarizes the current therapeutic strategies, but it is important to emphasize that the treatment recommendations must be tailored to the needs of individual patients.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000154
- to stream PascalFrancis, to step Curation: 000012
- to stream PascalFrancis, to step Checkpoint: 000156
Links to Exploration step
Pascal:01-0069947Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Parkinson's disease therapy : Tailoring choices for early and late disease, young and old patients</title><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">01-0069947</idno><date when="2000">2000</date><idno type="stanalyst">PASCAL 01-0069947 INIST</idno><idno type="RBID">Pascal:01-0069947</idno><idno type="wicri:Area/PascalFrancis/Corpus">000154</idno><idno type="wicri:Area/PascalFrancis/Curation">000012</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000156</idno><idno type="wicri:doubleKey">0362-5664:2000:Jankovic J:parkinson:s:disease</idno><idno type="wicri:Area/Main/Merge">001A01</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Parkinson's disease therapy : Tailoring choices for early and late disease, young and old patients</title><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></analytic><series><title level="j" type="main">Clinical neuropharmacology</title><title level="j" type="abbreviated">Clin. neuropharmacol.</title><idno type="ISSN">0362-5664</idno><imprint><date when="2000">2000</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Clinical neuropharmacology</title><title level="j" type="abbreviated">Clin. neuropharmacol.</title><idno type="ISSN">0362-5664</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term><term>Antiparkinson agent</term><term>Biological activity</term><term>Catechol O-methyltransferase</term><term>Chemotherapy</term><term>Cholinergic transmission</term><term>Controlled therapeutic trial</term><term>Dopamine receptor</term><term>Enzyme inhibitor</term><term>Human</term><term>Levodopa</term><term>MAO B inhibitor</term><term>Parkinson disease</term><term>Review</term><term>Selegiline</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term><term>Lévodopa</term><term>Antiparkinsonien</term><term>Sélégiline</term><term>IMAO B</term><term>Récepteur dopaminergique</term><term>Agoniste</term><term>Transmission cholinergique</term><term>Inhibiteur enzyme</term><term>Homme</term><term>Traitement</term><term>Chimiothérapie</term><term>Essai thérapeutique contrôlé</term><term>Activité biologique</term><term>Article synthèse</term><term>Catechol O-methyltransferase</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Advances in the understanding of basal ganglia circuitry and its altered function in disease states such as Parkinson's disease (PD), coupled with new insights into the mechanisms of cell death and new findings from therapeutic clinical trials, are being translated into clinical practice. Although levodopa (L-Dopa) remains the most effective drug in the symptomatic treatment of PD, the emergence of side effects, particularly motor fluctuations and dyskinesias, limits its usefulness. Therefore, many parkinsonologists now advocate therapeutic strategies designed to delay the onset of L-Dopa therapy to delay the onset of L-Dopa-related motor complications. The therapeutic approach to PD, however, must be individualized and based on factors such as age of the patient, stage of the disease, and degree of interference of the symptoms with social and occupational functioning, associated symptoms such as cognitive impairment, and response to treatment. This review summarizes the current therapeutic strategies, but it is important to emphasize that the treatment recommendations must be tailored to the needs of individual patients.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Texas</li></region><settlement><li>Houston</li></settlement><orgName><li>Baylor College of Medicine</li></orgName></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A01 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 001A01 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= Main
|étape= Merge
|type= RBID
|clé= Pascal:01-0069947
|texte= Parkinson's disease therapy : Tailoring choices for early and late disease, young and old patients
}}
| This area was generated with Dilib version V0.6.19. |  |